Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Change in Accured Expenses (2024 - 2025)

Historic Change in Accured Expenses for Neuphoria Therapeutics (NEUP) over the last 2 years, with Q4 2025 value amounting to $2.1 million.

  • Neuphoria Therapeutics' Change in Accured Expenses rose 36267.25% to $2.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.1 million, marking a year-over-year change of. This contributed to the annual value of $3.0 million for FY2025, which is 96173.64% up from last year.
  • Neuphoria Therapeutics' Change in Accured Expenses amounted to $2.1 million in Q4 2025, which was up 36267.25% from $718261.0 recorded in Q3 2025.
  • Neuphoria Therapeutics' 5-year Change in Accured Expenses high stood at $2.3 million for Q2 2025, and its period low was -$786378.0 during Q4 2024.